Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT

NCT04977986 is registered in ClinicalTrials.gov with Harmony Biosciences Management, Inc. as lead sponsor.

NCT NCT04977986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04977986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
Lead sponsor
Harmony Biosciences Management, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2021
Completion date
August 29, 2025
Enrollment
257 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome, fragile x syndrome (fxs)